{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:18:47Z","timestamp":1792091927588,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ijantimicag.2011.01.017","type":"journal-article","created":{"date-parts":[[2011,4,8]],"date-time":"2011-04-08T04:46:37Z","timestamp":1302237997000},"page":"389-395","source":"Crossref","is-referenced-by-count":39,"title":["Ceftaroline: a comprehensive update"],"prefix":"10.1016","volume":"37","author":[{"given":"Darpan","family":"Kaushik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.30.4.375","article-title":"Ceftaroline: a new cephalosporin with activity against resistant Gram-positive pathogens","volume":"30","author":"Steed","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0010","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1128\/AAC.01021-08","article-title":"In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing","volume":"53","author":"Brown","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0015","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1128\/AAC.00084-09","article-title":"Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new \u03b2-lactams that meet the challenge","volume":"53","author":"Llarrull","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0020","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(03)00126-3","article-title":"TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physiochemical and pharmacological properties","volume":"11","author":"Ishikawa","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0025","doi-asserted-by":"crossref","first-page":"9212","DOI":"10.1021\/ja8029448","article-title":"Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA \u03b2-lactam antibiotics","volume":"130","author":"Villegas-Estrada","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-004-0309-3","article-title":"In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599","volume":"10","author":"Iizawa","year":"2004","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0035","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/jac\/dki362","article-title":"Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disk diffusion tests","volume":"56","author":"Jones","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jac\/dkm150","article-title":"In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes","volume":"60","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0045","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0050","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"CANVAS-1: randomized, double-blinded, phase 3 study (P903-06) of the efficacy and safety of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSIs)","author":"Corey","year":"2008"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0055","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1128\/AAC.00636-09","article-title":"In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model","volume":"53","author":"Vidaillac","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0060","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.7164\/antibiotics.53.1053","volume":"53","author":"Ishikawa","year":"2000","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0065","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.7164\/antibiotics.53.1071","article-title":"Studies on anti-MRSA parenteral cephalosporins. II. Synthesis and antibacterial activity of 7\u03b2-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-(substituted imidazo[1,2-b]pyridazinium-1-yl)methyl-3-cephem-4-carboxylates and related compounds","volume":"53","author":"Ishikawa","year":"2000","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7164\/antibiotics.54.257","volume":"54","author":"Ishikawa","year":"2001","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0075","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7164\/antibiotics.54.364","article-title":"Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parenteral administration","volume":"54","author":"Ishikawa","year":"2001","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0080","unstructured":"World Health Organization. International nonproprietary names for pharmaceutical substances (INN): list 59. WHO Drug Information, vol. 22, no. 1. Geneva: WHO; 2008."},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0085","unstructured":"Forest Laboratories, Inc. Soluble dosage forms containing cephem derivatives suitable for parenteral administration. USPTO Patent Application 20090082326. http:\/\/www.frx.com [accessed 8 February 2011]."},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0090","series-title":"An introduction to medicinal chemistry","author":"Patrick","year":"2005"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/14728214.12.4.511","article-title":"Emerging cephalosporins","volume":"12","author":"Page","year":"2007","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","article-title":"The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis","volume":"32","author":"Sauvage","year":"2008","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/MMBR.66.4.702-738.2002","article-title":"Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent","volume":"66","author":"Goffin","year":"2002","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.42.1.1","article-title":"Kinship and diversification of bacterial penicillin-binding proteins and \u03b2-lactamases","volume":"42","author":"Massova","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0115","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1128\/CMR.16.4.673-687.2003","article-title":"Bacterial wall as target for attack: past, present, and future research","volume":"16","author":"Koch","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-6968.2008.01384.x","article-title":"Pathogenomics of the staphylococci: insights into niche adaptation and the emergence of new virulent strains","volume":"289","author":"Ben Zakour","year":"2008","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0125","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.mib.2007.08.003","article-title":"Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power","volume":"10","author":"de Lencastre","year":"2007","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0130","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/46th annual meeting of the Infectious Diseases Society of America (IDSA)","article-title":"Binding of ceftaroline (CPT) to penicillin-binding proteins (PBPs) of Streptococcus pneumoniae (SPN) and methicillin-resistant Staphylococcus aureus (MRSA)","author":"Moisan","year":"2008"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0135","unstructured":"Clinical and Laboratory Standards Institute. http:\/\/www.clsi.org [accessed 8 February 2011]."},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0140","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/jac\/dkq193","article-title":"Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis","volume":"65","author":"Jacqueline","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0145","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1128\/AAC.00645-09","article-title":"Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection","volume":"54","author":"Ge","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0150","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/AAC.00984-09","volume":"53","author":"Jacqueline","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0155","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1128\/AAC.01242-06","article-title":"In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model","volume":"51","author":"Jacqueline","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0160","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/AAC.01351-07","article-title":"Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus","volume":"52","author":"Sader","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0165","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States","volume":"52","author":"Ge","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0170","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.48.8.2831-2837.2004","article-title":"In vitro activities of ME1036 CP5609, a novel parenteral carbapenem, against methicillin-resistant staphylococci","volume":"48","author":"Kurazono","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0175","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Evaluation of the bactericidal activity of the novel cephalosporin ceftaroline PPI\u20130903M, compared to ceftriaxone against Streptococcus pneumonia","author":"Sader","year":"2006"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/10408410902733979","article-title":"\u03b2-Lactams and \u03b2-lactamase inhibitors in current- or potential-clinical practices: a comprehensive update","volume":"35","author":"Shahid","year":"2009","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0185","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijantimicag.2008.12.005","article-title":"Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia","volume":"33","author":"Morrissey","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/41.suppl_4.25","article-title":"\u03b2-Lactamase-mediated resistance and opportunities for its control","volume":"41","author":"Livermore","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0195","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/46th annual meeting of the Infectious Diseases Society of America (IDSA)","article-title":"Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline","author":"Hinshaw","year":"2008"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0200","doi-asserted-by":"crossref","first-page":"40802","DOI":"10.1074\/jbc.M403589200","article-title":"The basis for resistance to \u03b2-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus","volume":"279","author":"Fuda","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1574-6976.2007.00095.x","article-title":"Penicillin-binding proteins and \u03b2-lactam resistance","volume":"32","author":"Zapun","year":"2008","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0210","doi-asserted-by":"crossref","first-page":"10886","DOI":"10.1073\/pnas.191260798","article-title":"An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci","volume":"98","author":"Pinho","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0215","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s00018-005-5148-6","article-title":"\u03b2-Lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome","volume":"62","author":"Fuda","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0220","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jac\/dkq161","article-title":"Activity of chequerboard combinations of ceftaroline and NXL104 versus \u03b2-lactamase-producing Enterobacteriaceae","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0225","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subject","author":"Ge","year":"2006"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0230","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subject receiving multiple dose intravenous infusion","author":"Ge","year":"2006"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0235","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/46th annual meeting of the Infectious Diseases Society of America (IDSA)","article-title":"A single and multiple dose study to determine the safety, tolerability and pharmacokinetics (PK) of ceftaroline (PPI-0903) administered by intramuscular injection to healthy subjects","author":"Riccobene","year":"2008"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0240","series-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Population pharmacokinetic (PK) analysis of ceftaroline (PPI-0903) in volunteers and patients with complicated skin and skin structure infection","author":"Ge","year":"2007"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0245","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Penetration of ceftaroline, a new cephalosporin, in to lung tissue: measurement of plasma and lung tissue concentration after a short i.v infusion in rabbit","author":"Jacqueline","year":"2006"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0250","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI)","author":"Ge","year":"2006"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0255","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.50.4.1376-1383.2006","article-title":"Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic\u2013pharmacodynamic target","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0260","series-title":"European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"CANVAS-2: randomized, double-blinded, phase 3 study (P903-07) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections","author":"Wilcox","year":"2009"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0265","series-title":"49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP)","author":"Eckburg","year":"2009"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0270","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0275","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline","author":"Ge","year":"2006"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0280","series-title":"European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"An open-label, pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis","author":"Riccobene","year":"2009"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0285","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.01516-09","article-title":"In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates","volume":"54","author":"Saravolatz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0290","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01797-09","article-title":"Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States","volume":"54","author":"Jacobs","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0295","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0300","first-page":"A2273","article-title":"FOCUS 1: randomized, double-blinded, multicenter phase 3 study of the efficacy and safety of ceftaroline vs ceftriaxone in community-acquired bacterial pneumonia","volume":"181","author":"Eckburg","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0305","first-page":"A5482","article-title":"Serotypes and antimicrobial susceptibility of Streptococcus pneumoniae isolates from FOCUS 1 and 2. Two international trials of ceftaroline in patients hospitalized for community-acquired bacterial pneumonia","volume":"181","author":"Jacobs","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0310","series-title":"49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Spectrum and activity of ceftaroline combined with NXL 104 tested against a challenge collection of pathogens with well characterized resistance","author":"Sader","year":"2009"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0315","series-title":"49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Bactericidal activity of ceftaroline combined with NXL 104 against critical targeted organisms possessing various resistance mechanisms","author":"Castanheira","year":"2009"},{"key":"10.1016\/j.ijantimicag.2011.01.017_bib0320","unstructured":"Forest Laboratories, Inc. Novexel's NXL104\/ceftazidime combination commences phase II clinical trials in hospital patient with complicated urinary tract infections. Press release 2008. http:\/\/www.frx.com [accessed 8 February 2011]."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857911000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857911000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T17:00:23Z","timestamp":1560099623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857911000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0924857911000719"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.01.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}